MX2022010556A - Uso de peptidilglicina alfa-amidante monooxigenasa (pam) para proposito terapeutico. - Google Patents

Uso de peptidilglicina alfa-amidante monooxigenasa (pam) para proposito terapeutico.

Info

Publication number
MX2022010556A
MX2022010556A MX2022010556A MX2022010556A MX2022010556A MX 2022010556 A MX2022010556 A MX 2022010556A MX 2022010556 A MX2022010556 A MX 2022010556A MX 2022010556 A MX2022010556 A MX 2022010556A MX 2022010556 A MX2022010556 A MX 2022010556A
Authority
MX
Mexico
Prior art keywords
pam
therapeutic purpose
amidating monooxygenase
peptidylglycine alpha
disorder
Prior art date
Application number
MX2022010556A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
Pam Theragnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pam Theragnostics Gmbh filed Critical Pam Theragnostics Gmbh
Publication of MX2022010556A publication Critical patent/MX2022010556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/17—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced ascorbate as one donor, and incorporation of one atom of oxygen (1.14.17)
    • C12Y114/17003—Peptidylglycine monooxygenase (1.14.17.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a peptidilglicina alfa-amidante monooxigenasa (PAM) para usarse como un medicamento y el tratamiento de un sujeto, en donde el tratamiento comprende: reducir el potencial o riesgo de una enfermedad o trastorno, y/o reducir la ocurrencia de una enfermedad o trastorno, y/o reducir la gravedad de una enfermedad o trastorno.
MX2022010556A 2020-02-26 2021-02-26 Uso de peptidilglicina alfa-amidante monooxigenasa (pam) para proposito terapeutico. MX2022010556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159647 2020-02-26
PCT/EP2021/054869 WO2021170816A1 (en) 2020-02-26 2021-02-26 Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose

Publications (1)

Publication Number Publication Date
MX2022010556A true MX2022010556A (es) 2022-11-30

Family

ID=69740297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010556A MX2022010556A (es) 2020-02-26 2021-02-26 Uso de peptidilglicina alfa-amidante monooxigenasa (pam) para proposito terapeutico.

Country Status (11)

Country Link
US (1) US20230149516A1 (es)
EP (1) EP4110372A1 (es)
JP (1) JP2023516007A (es)
KR (1) KR20220146538A (es)
CN (1) CN115243709A (es)
AU (1) AU2021227101A1 (es)
BR (1) BR112022015949A2 (es)
CA (1) CA3168769A1 (es)
IL (1) IL295924A (es)
MX (1) MX2022010556A (es)
WO (1) WO2021170816A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133235A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Adm-gly as marker for early predicting sepsis
WO2025133215A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Use of inactive adrenomedullin precursor for therapeutic purposes
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) * 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) * 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5612186A (en) 1994-06-22 1997-03-18 Food Industry Research And Development Institute Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples
US5601986A (en) 1994-07-14 1997-02-11 Amgen Inc. Assays and devices for the detection of extrahepatic biliary atresia
EP2141814B1 (en) 2008-07-01 2011-11-16 TELEFONAKTIEBOLAGET LM ERICSSON (publ) Delta-sigma analog-to-digital converter, radio receiver, communication apparatus, method, and computer program
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
ES2583259T3 (es) * 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
CN105393117A (zh) 2013-01-31 2016-03-09 凯普里昂蛋白质组学公司 2型糖尿病生物标志物及其用途
WO2015091131A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Use of peptidylglycine alpha-amidating monooxigenase (pam) for c-terminal amidation
EP3092494A4 (en) 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
WO2019154900A1 (en) 2018-02-08 2019-08-15 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
CN114174326A (zh) 2019-06-18 2022-03-11 拜耳公司 长期稳定的肾上腺髓质素类似物及其用途
JP2023515981A (ja) * 2020-02-26 2023-04-17 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンαアミド化モノオキシゲナーゼ（ＰＡＭ）を決定する方法および診断目的でのその使用

Also Published As

Publication number Publication date
EP4110372A1 (en) 2023-01-04
IL295924A (en) 2022-10-01
WO2021170816A1 (en) 2021-09-02
US20230149516A1 (en) 2023-05-18
CA3168769A1 (en) 2021-09-02
KR20220146538A (ko) 2022-11-01
CN115243709A (zh) 2022-10-25
JP2023516007A (ja) 2023-04-17
AU2021227101A1 (en) 2022-10-20
BR112022015949A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2022010556A (es) Uso de peptidilglicina alfa-amidante monooxigenasa (pam) para proposito terapeutico.
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
GEP20166426B (en) Pirfenidone therapy and inducers of cytochrome p450
MX2023008726A (es) Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2024015041A (es) Fitusiran para el tratamiento de la hemofilia a y b
PH12022550045A1 (en) Plasma kallikrein inhibitors
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
WO2023285654A3 (en) Compounds for the treatment of covid-19
WO2022165434A3 (en) Fc-enhanced antibodies for prevention and treatment of ebola virus infection
CR20230121A (es) Tratamiento de la enfermedad de parkinson
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
MY203821A (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2023010371A (es) Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
BR112022019660A2 (pt) Composições e métodos para tratamento de câncer
MX2022010437A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.